Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Surgical Procedures | 1 | 2018 | 10 | 0.610 |
Why?
|
| Aerococcus | 1 | 2017 | 2 | 0.600 |
Why?
|
| Aneurysm, Infected | 1 | 2017 | 14 | 0.590 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 26 | 0.590 |
Why?
|
| Aortic Aneurysm | 1 | 2017 | 25 | 0.590 |
Why?
|
| Aneurysm, False | 1 | 2017 | 43 | 0.570 |
Why?
|
| Endocarditis, Bacterial | 1 | 2017 | 45 | 0.570 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2016 | 9 | 0.550 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 34 | 0.540 |
Why?
|
| Hypolipidemic Agents | 1 | 2016 | 27 | 0.540 |
Why?
|
| Dyslipidemias | 1 | 2016 | 36 | 0.530 |
Why?
|
| Heart Arrest | 1 | 2018 | 151 | 0.530 |
Why?
|
| Cardiac Catheterization | 1 | 2018 | 214 | 0.520 |
Why?
|
| Cardiovascular Diseases | 2 | 2017 | 443 | 0.470 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 460 | 0.410 |
Why?
|
| Hypertension | 2 | 2017 | 537 | 0.180 |
Why?
|
| Percutaneous Coronary Intervention | 2 | 2016 | 301 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2017 | 5155 | 0.170 |
Why?
|
| Cyclonic Storms | 1 | 2018 | 6 | 0.160 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2017 | 22 | 0.150 |
Why?
|
| Aortography | 1 | 2017 | 35 | 0.150 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 60 | 0.140 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 62 | 0.140 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2017 | 78 | 0.140 |
Why?
|
| Medication Adherence | 1 | 2017 | 130 | 0.130 |
Why?
|
| Aortic Valve | 1 | 2017 | 112 | 0.130 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2017 | 119 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2017 | 170 | 0.130 |
Why?
|
| Information Dissemination | 1 | 2016 | 79 | 0.130 |
Why?
|
| Inpatients | 1 | 2017 | 190 | 0.130 |
Why?
|
| Drug-Eluting Stents | 1 | 2016 | 93 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2016 | 88 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 200 | 0.130 |
Why?
|
| Social Media | 1 | 2016 | 96 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 225 | 0.120 |
Why?
|
| Registries | 1 | 2017 | 522 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 396 | 0.120 |
Why?
|
| Risk Factors | 3 | 2018 | 3629 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 268 | 0.120 |
Why?
|
| Humans | 10 | 2018 | 50208 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 276 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2013 | 119 | 0.100 |
Why?
|
| Pandemics | 1 | 2016 | 562 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 747 | 0.100 |
Why?
|
| Models, Biological | 1 | 2014 | 723 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2013 | 214 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 286 | 0.080 |
Why?
|
| Male | 6 | 2018 | 25399 | 0.080 |
Why?
|
| Adult | 3 | 2018 | 13324 | 0.070 |
Why?
|
| United States | 3 | 2017 | 4874 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2018 | 6134 | 0.050 |
Why?
|
| Animals | 1 | 2016 | 13246 | 0.050 |
Why?
|
| Female | 5 | 2018 | 26635 | 0.040 |
Why?
|
| New Orleans | 1 | 2018 | 5 | 0.040 |
Why?
|
| Awareness | 1 | 2017 | 28 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 111 | 0.040 |
Why?
|
| Social Class | 1 | 2017 | 93 | 0.030 |
Why?
|
| Absorbable Implants | 1 | 2016 | 16 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 121 | 0.030 |
Why?
|
| Coronary Restenosis | 1 | 2016 | 31 | 0.030 |
Why?
|
| Tissue Scaffolds | 1 | 2016 | 34 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2016 | 85 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 407 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2016 | 237 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1006 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 901 | 0.030 |
Why?
|
| MEDLINE | 1 | 2014 | 8 | 0.030 |
Why?
|
| India | 1 | 2014 | 51 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1422 | 0.030 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2013 | 12 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 550 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2013 | 17 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2013 | 47 | 0.030 |
Why?
|
| Ticlopidine | 1 | 2013 | 55 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 324 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 1954 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2190 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2013 | 166 | 0.030 |
Why?
|
| Aged | 2 | 2017 | 9405 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 951 | 0.020 |
Why?
|
| Middle Aged | 2 | 2018 | 12206 | 0.020 |
Why?
|
| Thrombosis | 1 | 2013 | 248 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 3154 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 2379 | 0.020 |
Why?
|